Market Overview:
GVHD is a complication that can occur after a stem cell or bone marrow transplant. In GVHD, the donor cells (graft) recognize the recipient's cells (host) as foreign and attack them. This can lead to serious health problems, including death. There are two types of GVHD: acute and chronic. The global graft versus host disease treatment market is expected to grow from USD 1,527 million in 2018 to USD 2,853 million by 2030 at a CAGR of 8.9%, according to MarketsandMarkets™ research study on graft versus host disease treatment market.
 Treatment Industry Outlook.svg)
Product Definition:
GVHD is a complication that can occur after a bone marrow transplant. Grafts are transplanted cells from either the patient or a donor. Hosts are the recipients of these grafts. In some cases, the transplanted cells may begin to attack the hosts' tissues, leading to GVHD.
There are treatments available for GVHD, but they vary depending on its severity.
Monoclonal Antibodies:
Monoclonal antibodies are a type of interleukin (IL) family member. They are produced by the B cells of the immune system in response to antigen stimulation. There are several types of monoclonal antibodies, distinguished on the basis of their specificity and binding properties. The most commonly used monoclonal antibody is Rituximab manufactured by Roche which targets CD20 (B-cell malignancy).
MTOR Inhibitors:
The market for MTOR inhibitors and it's usage in Graft Versus Host Disease (GVHD) treatment was valued at USD 1.8 billion in 2016 and is expected to grow at a CAGR of XX% during the forecast period.
Application Insights:
The acute graft versus host disease (aGvHD) segment dominated the global market in 2017 and is expected to maintain its lead over the forecast period. The aGvHD treatment market is driven by an increase in awareness about GVHD, growing product adoption, and favorable government initiatives. For instance, according to WHO, around 60% of patients developed some form of GVHD after solid organ transplantation; however, only 25% of them received any treatment for it. As a result, many governments have implemented programs such as Living Donor Transplantation without Live-Donor Assistance (LDW), which has increased the number of transplants performed worldwide.
The chronic graft versus host disease (cGVHD) segment is anticipated to witness lucrative growth during the forecast period due to increasing incidence rates of cGVHD across various applications including kidney transplantation and liver transplantation procedures.
Regional Analysis:
North America dominated the global GVHD treatment market in 2017. This can be attributed to the presence of key players, availability of novel therapies, high healthcare expenditure and better reimbursement policies. Moreover, increasing incidence of acute and chronic GVHD has led to an increase in demand for immunosuppressant drugs leading to growth in this region. For instance, according to data published by National Institute of Health (NIH), from January 2014 till December 2015 approximately 12 million people were diagnosed with cancer worldwide which resulted into around 7 million deaths due to various causes including smoking and unhealthy lifestyle resulting into a huge economic loss every year.
Growth Factors:
- Increasing incidence of GVHD
- Rising awareness about GVHD and its treatment options
- Growing demand for better and more effective treatments for GVHD
- Availability of novel therapies and treatments for GVHD
- increasing investment in research and development for new therapies to treat GVHD
Scope Of The Report
Report Attributes
Report Details
Report Title
Graft Versus Host Disease (GVHD) Treatment Market Research Report
By Type
Monoclonal Antibodies, MTOR Inhibitors, Tyrosine Kinase Inhibitors, Thalidomide, Etanercept
By Application
Acute Graft Versus Host Disease (aGvHD), Chronic Graft Versus Host Disease (cGvHD)
By Companies
Bristol-Myers Squibb, Abbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Caladrius, Eli Lilly, GlaxoSmithKline, Glenmark, Kadmon Holdings, Osiris Therapeutics, Sanofi, Takeda
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Graft Versus Host Disease (GVHD) Treatment Market Report Segments:
The global Graft Versus Host Disease (GVHD) Treatment market is segmented on the basis of:
Types
Monoclonal Antibodies, MTOR Inhibitors, Tyrosine Kinase Inhibitors, Thalidomide, Etanercept
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Graft Versus Host Disease (aGvHD), Chronic Graft Versus Host Disease (cGvHD)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Abbott
- AbbVie
- Allergan
- Anterogen
- Astellas Pharma
- Athersys
- Caladrius
- Eli Lilly
- GlaxoSmithKline
- Glenmark
- Kadmon Holdings
- Osiris Therapeutics
- Sanofi
- Takeda
 Treatment Market Overview.svg)
Highlights of The Graft Versus Host Disease (GVHD) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- MTOR Inhibitors
- Tyrosine Kinase Inhibitors
- Thalidomide
- Etanercept
- By Application:
- Acute Graft Versus Host Disease (aGvHD)
- Chronic Graft Versus Host Disease (cGvHD)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Graft Versus Host Disease (GVHD) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Graft versus host disease (GVHD) treatment is the process of treating a patient who has developed GVHD after receiving a transplant. Treatment typically includes aggressive anti-inflammatory therapy and immunosuppressive drugs to prevent the development of additional GVHD episodes.
Some of the major companies in the graft versus host disease (gvhd) treatment market are Bristol-Myers Squibb, Abbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Caladrius, Eli Lilly, GlaxoSmithKline, Glenmark, Kadmon Holdings, Osiris Therapeutics, Sanofi, Takeda.
The graft versus host disease (gvhd) treatment market is expected to register a CAGR of 8.9%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Graft Versus Host Disease (GVHD) Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Graft Versus Host Disease (GVHD) Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Graft Versus Host Disease (GVHD) Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Graft Versus Host Disease (GVHD) Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Graft Versus Host Disease (GVHD) Treatment Market Size & Forecast, 2018-2028
4.5.1 Graft Versus Host Disease (GVHD) Treatment Market Size and Y-o-Y Growth
4.5.2 Graft Versus Host Disease (GVHD) Treatment Market Absolute $ Opportunity
Chapter 5 Global Graft Versus Host Disease (GVHD) Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 MTOR Inhibitors
5.2.3 Tyrosine Kinase Inhibitors
5.2.4 Thalidomide
5.2.5 Etanercept
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Graft Versus Host Disease (GVHD) Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Applications
6.2.1 Acute Graft Versus Host Disease (aGvHD)
6.2.2 Chronic Graft Versus Host Disease (cGvHD)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Graft Versus Host Disease (GVHD) Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Graft Versus Host Disease (GVHD) Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 MTOR Inhibitors
9.6.3 Tyrosine Kinase Inhibitors
9.6.4 Thalidomide
9.6.5 Etanercept
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Applications
9.10.1 Acute Graft Versus Host Disease (aGvHD)
9.10.2 Chronic Graft Versus Host Disease (cGvHD)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Graft Versus Host Disease (GVHD) Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 MTOR Inhibitors
10.6.3 Tyrosine Kinase Inhibitors
10.6.4 Thalidomide
10.6.5 Etanercept
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Applications
10.10.1 Acute Graft Versus Host Disease (aGvHD)
10.10.2 Chronic Graft Versus Host Disease (cGvHD)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Graft Versus Host Disease (GVHD) Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 MTOR Inhibitors
11.6.3 Tyrosine Kinase Inhibitors
11.6.4 Thalidomide
11.6.5 Etanercept
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Applications
11.10.1 Acute Graft Versus Host Disease (aGvHD)
11.10.2 Chronic Graft Versus Host Disease (cGvHD)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Graft Versus Host Disease (GVHD) Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 MTOR Inhibitors
12.6.3 Tyrosine Kinase Inhibitors
12.6.4 Thalidomide
12.6.5 Etanercept
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Applications
12.10.1 Acute Graft Versus Host Disease (aGvHD)
12.10.2 Chronic Graft Versus Host Disease (cGvHD)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Graft Versus Host Disease (GVHD) Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 MTOR Inhibitors
13.6.3 Tyrosine Kinase Inhibitors
13.6.4 Thalidomide
13.6.5 Etanercept
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Graft Versus Host Disease (GVHD) Treatment Market Size Forecast by Applications
13.10.1 Acute Graft Versus Host Disease (aGvHD)
13.10.2 Chronic Graft Versus Host Disease (cGvHD)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Graft Versus Host Disease (GVHD) Treatment Market: Competitive Dashboard
14.2 Global Graft Versus Host Disease (GVHD) Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 Abbott
14.3.3 AbbVie
14.3.4 Allergan
14.3.5 Anterogen
14.3.6 Astellas Pharma
14.3.7 Athersys
14.3.8 Caladrius
14.3.9 Eli Lilly
14.3.10 GlaxoSmithKline
14.3.11 Glenmark
14.3.12 Kadmon Holdings
14.3.13 Osiris Therapeutics
14.3.14 Sanofi
14.3.15 Takeda
